Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bicifadine SR in Diabetic Neuropathy
NCT00553592Phase 2Unknown
- Sponsor
- XTL Biopharmaceuticals Ltd.
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bicifadine in diabetic peripheral neuropathy (DPN) (3 arms), sponsored by XTL Biopharmaceuticals Ltd. Primary endpoints: Reduction of chronic neuropathic pain measured by a daily rating of pain intensity at 14 weeks and Safety at 14 weeks. Status: unknown.
02
Drugs
bicifadine
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT00553592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00553592.